Psychiatr. pro Praxi, 2010; 11(2): 77-82

Concerta in the treatment hyperkinetic disorder/ADHD in children and adolescents

prof.MUDr.Ivana Drtílková, CSc.
Psychiatrická klinika FN Brno a LF Masarykovy univerzity v Brně

CONCERTA® is a once-daily, long-acting formulation of methylphenidate and indicated for the treatment of ADHD in children from six

years and adolescents. The osmotic release oral system (OROS) methylphenidate formulation is designed to deliver methylphenidate

in a controlled manner for approximately 12 hours, thereby allowing extended coverage of symptoms ADHD during the day. Compared

to methylphenidate IR the new OROS formulation of methylphenidate brings numerous benefits: simple dosage improves adherence

to treatment, reduces risks of stigmatization and misuse and the stability of serum levels of the medication contributes to a more pronounced

effect on neurocognitive and behavioral symptoms of ADHD and improves tolerability and compliance.

Keywords: methylphenidate, OROS system, Concerta, ADHD

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I. Concerta in the treatment hyperkinetic disorder/ADHD in children and adolescents. Psychiatr. praxi. 2010;11(2):77-82.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Greenhill LL, Pliszca S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(2 suppl): 26S-49S. Go to original source... Go to PubMed...
    2. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur. Neuropsychopharmacol. 2004; 14: 11-28. Go to original source... Go to PubMed...
    3. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073-1086. Go to original source... Go to PubMed...
    4. Concerta - SPC, poslední revize textu 16. 7. 2008.
    5. Mezinárodní klasifikace nemocí, 10. revize. Duševní poruchy a poruchy chování. Popisy klinických příznaků a diagnostická vodítka (překl. z anglického originálu). Praha, Psychiatrické centrum 1992: 282.
    6. American Psychiatric Association: Diagnostic and Statistic Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, D.C., American Psychiatric Association 1994.
    7. Hrdlička M. Hyperkinetická porucha - komorbidity a diferenciální diagnostika. In: Raboch J, Zrzavecká I, Doubek P. Nemocná duše - nemocný mozek: klinická zkušenost a fakta. Sborník 6. sjezdu Psychiatrické společnosti ČLS JEP, Špindlerův Mlýn, 8.-11. 6. 2006. 1. vyd., Praha, Galén 2006: 52-54.
    8. American Academy of Child and Adolescent Psychiatry (AACAP): Practice parameters for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2007; 46: 894-921. Go to original source... Go to PubMed...
    9. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder. NICE clinical guideline 72. London, NICE 2008.
    10. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur. Child Adolesc. Psychiatry 2004; 14(Suppl. 1): 7-30. Go to original source... Go to PubMed...
    11. Drtílková I, Hrdlička M, Paclt I. Hyperkinetické poruchy u dětí. In: Psychiatrie, Doporučené postupy psychiatrické péče II 2006: 141-149. Aktualizace 2009 (v tisku).
    12. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylfenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs study). Pediatrics 2004; 113: 206-216. Go to original source... Go to PubMed...
    13. Steele M, Weiss M, Swanson J, et al. Randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release-methylphenidate in ADHD. J Clin Pharmacol 2006; 13(1): e50-e62.
    14. Spencer TJ, et al. PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate. Am J Psychiatry 2006; 163: 387-395. Go to original source... Go to PubMed...
    15. Auiler JF, Liu K, Lynch JM, Gelotte CK. Extended-Release Stimulants: Results from the Concerta(R), Adderall XR(TM) Food Evaluation (CAFÉ) Study Current Medical Research and Opinion 2002; (18)5: 311-316. Go to original source... Go to PubMed...
    16. Nissen SE. ADHD drugs and cardiovascular risk. N Engl JMed 2006; 354: 1445-1448. Go to original source... Go to PubMed...
    17. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005; 66: 253-259. Go to original source... Go to PubMed...
    18. Greenhill LL, Findling RL, Swanson JM. A Double-Blind, Placebo-Controlled Study of Modified-Release Methylphenidate in Children With Attention Deficit/Hyperactivity Disorder. Pediatrics 2002; 109: e39. Go to original source... Go to PubMed...
    19. Wolraich ML, Greenhill LL, Pelham WL, et al. Randomized, controlled trial of Oros methylphenidate once a day in children with attention-deficit hyperactivity disorder. Pediatrics 2001; 108: 883-892. Go to original source... Go to PubMed...
    20. Wolraich ML, McGuinn, L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety consideration. Drug Safety. 2007; 30: 17-26. Go to original source... Go to PubMed...
    21. Sachachar R, Tannock R, Cunningham C, Corkum P. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J. Am. Acad. Child Adolesc. Psychiatry 1997; 36: 754-763. Go to original source... Go to PubMed...
    22. Swanson J, Greenhill L, Pelham WE. Initiating Concerta (OROS methylphenidate HCl) qd in children with attentiondeficit/hyperactivity disorder. Journal of Clinical Research 2000; 3: 59-76.
    23. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Oncea-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings. Pediatrics 2001; 107(6): e105. Go to original source... Go to PubMed...
    24. Remschmidt H, Hoare P, Dytrich C, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS(R) MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 2005; 14: 297-304. Go to original source... Go to PubMed...
    25. Yeni Kim, Min-Sup Shin, Jae-Won Kim. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum. Psychopharmacol Clin Exp 2009; 24: 95-102. Go to original source... Go to PubMed...
    26. Stein MA, Sarampote, CHS, Waldman ID, et al. A DoseResponse Study of OROS Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder. Pediatrics 2003; 112(5): e404-e404. Go to original source... Go to PubMed...
    27. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977; 23(198) 4323: 1274-1276. Go to original source... Go to PubMed...
    28. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Advances in Therapy 2005; 22(5): 498-512. Go to original source... Go to PubMed...
    29. Staarr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: Treatment outcomes in African-American children with ADHD. Journal of the National Medical Association CODEN JNMAAE 2005; 97(10)supp.: 11S-16S.
    30. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur. Child Adolesc. Psychiatry 15; 2006: 476-495. Go to original source... Go to PubMed...
    31. Newcorn JH, Kratochvil ChJ, Allen AJ, et al. Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperaktivity Disorder: Acute Comparison and Differential Response. Am J Psychiatry 2008; 165: 721-730. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.